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Each year, a cohort in the Northern Cape undergo colonoscopies as part of a surveillance 
program for individuals who have a C1528T mutation in the hMLH1 gene that puts them at 
very high risk for the development of colon cancer (Lynch syndrome).  A clean colon is 
essential as it allows a thorough evaluation and surveillance for small polyps or mucosal 
lesions mostly encountered in the ascending colon.  This study evaluated both the subject 
acceptance and the effectiveness of a 2L PEG electrolyte lavage solution containing ascorbic 
acid and sodium ascorbate (Moviprep®) as a preparation solution.  
 
Methods: 
The screening program was divided into two stages.  
 
Stage 1, 71 subjects were counselled individually on the importance of bowel cleansing and 
the use of Moviprep® as their bowel cleansing agent.  Preparation was either a) 2L the night 
prior to colonoscopy or b) 1L the night prior to and the second litre on the morning of the 
colonoscopy.  Subjects were encouraged to drink at least 500ml clear fluid in addition to each 
litre of Moviprep®.  Informed consent was obtained for participation in the study.  
  
Stage 2, approximately 6 weeks later, each subject completed a questionnaire, evaluating 
their experience with Moviprep® and also had their screening colonoscopy performed.  
Colonoscopies were performed at 4 medical facilities in the Northern Cape. All subjects were 
assessed for bowel cleanliness on arrival at the facility where colonoscopy was to be 
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performed.  If any of the subjects were found to be inadequately cleaned, extra oral 
preparation was given prior to colonoscopy.   
The Harefield cleansing scale was used to evaluate the quality of colonic cleansing during 
each colonoscopy.  The colon was divided into 6 segments (rectum, sigmoid, descending-, 
transverse-, ascending colon and cecum).  Preparation was scored as A = all colon segments 
clean; B = at least 1 segment with residual amounts of brown liquid or semisolid stool, which 
can easily be displaced or removed; C = at least 1 segment with only partially removable 
stool, preventing complete visualization; D = at least 1 segment which could not be examined 
due to solid stool).  Grades A or B were considered successful cleansing and grades C or D 
were considered a failed colonic preparation.   
Results: 
A total of 46 subjects had colonoscopies performed.  41(89%) of them had successful and 
5(11%) failed preparation.  Three of those subjects that prepared successfully had previously 
undergone right hemicolectomies, leaving 38 with intact colons.  22/38 (58%) subjects 
achieved an A grade for caecal cleansing and 16/38 (42%) a B grading.  24\38 (63%) subjects 
scored an A grade for the ascending colon and 14/38 (37%) a B grade.   
A total of 64 subjects completed the questionnaires of which 83% (53/64) had used other 
colon preparations previously.   When asked if they would use Moviprep® again in the 
future, 89% (57/64) said yes and 11% (7/64) said no.  94% of subjects (60/64) would 
recommend Moviprep® to friend and family. 
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Moviprep® provided adequate colonic cleansing in 89% of subjects.  In addition, nearly 90% 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1. INTRODUCTION and LITERATURE REVIEW
1.1  Lynch syndrome 
Ten to twenty percent of colorectal cancers appear to have evidence of genetic predisposition. 
The most common inherited precursors of Colorectal Cancers (CRCs) are Familial 
Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colon Cancer or Lynch 
Syndrome (LS). 1-6 
Both FAP and LS are the result of specific germ line mutations.  FAP, as inherited precursor,  
accounts for less than 1% of CRC’s.  LS is the most common form of inherited precursor 
colorectal cancer, accounting for 2 – 7% of all colorectal cancers diagnose in the U.S. 
annually. 1-3 
Hereditary Non-Polyposis Colon Cancer or Lynch Syndrome is an inherited bowel cancer 
syndrome and arises from a mutation in the mismatch repair genes.  It is an autosomal 
dominant condition and is characterized by the development of colorectal cancer in patients 
at a young age.   Extra colonic malignancies also commonly occur. 1   If a patient is found to 
have a mutation or defect in the mismatch repair gene, he or she might belong to a Lynch 
Syndrome family.  Germ-line mutations in any of four DNA mismatch repair genes, MLH1, 
MSH2, MSH6 and PMS2, may be responsible for Lynch syndrome. 7   Carriers of a mismatch 
repair gene mutation in MLH1 or MSH2 have a lifetime risk of 85 – 90% risk of developing 
any type of cancer. 7    
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The most frequent cancer amongst Lynch Syndrome patients are colorectal- and endometrial 
cancer with a respective cumulative risk of 60 – 80% and 30 – 50%.  7 
Colonoscopic surveillance significantly reduces the incidence of colorectal cancer and 
increases survival. 7   The presence of a mismatch repair mutation may alter the extent of 
surgery and type of adjuvant chemotherapeutic agents used in young patients with colorectal 
carcinoma.  The DNA mismatch repair mutation plays a role in the toxicity of a number of 
DNA-damaging drugs that might be considered in cancer chemotherapy.   8-9  
Also, one might consider more extensive resection in this group of patients, as they are young 
and have a higher risk of developing another cancer in the future.   
Previous studies have identified a cohort of individuals with Lynch Syndrome as a result of a 
C1528T mutation in the hMLH1 gene who live in the Northern Cape. 10   Those at risk for the 
development of colonic carcinoma are offered annual screening colonoscopy (biennial if 
under 30).  The lesions/polyps are most prevalent in the right side of the colon hence 
emphasizing the importance of proper and complete colon preparation prior to    
colonoscopy. 10
1.2  Options for early detection of colonic disease 
Multiple screening modalities are available aimed at early detection of colorectal carcinoma, 
but few are specific with regard to establishing the diagnoses of colorectal carcinoma. 
Screening of the general population is not feasible in the South African context due to cost 
involved and limited recourses.  Patients are thus risk stratified into either high or low risk for 
the probability of development or presence of colorectal carcinoma. Clinical history,  
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presentation and examination play a major role in this risk stratification process which 
identifies patients for surveillance.   
Surveillance modalities range from minimally invasive laboratory testing, such as tumour 
markers and stool for occult blood, to more invasive modalities such as contrast enemas, 
flexible sigmoidoscopy, CT colography and colonoscopy.   
Considering the rural location of our study population and minimal access to health care 
facilities, modalities other than colonoscopy, are not practical or definitive enough as a single 
surveillance modality.  These would include both faecal occult blood and contrast enemas.  
CT colonography, which is also known as virtual colonoscopy, reconstructs an interior view 
of the colon by utilizing low dose radiation CT scanning.  Again, this would only be possible 
in a tertiary medical institution.  More than 95% of colorectal cancers arise from benign 
adenomatous polyps.  These polyps grow very slowly and may develop over many years.  A 
powerful method of secondary prevention of the development of colorectal cancer within 
these adenomatous polyps, is interruption of the adenoma-carcinoma sequence.  This is 
accomplished by resecting adenomatous polyps.  The procedure of choice for the diagnosis 
and resection of colorectal polyps is Colonoscopy. 11  
For individuals with Lynch syndrome, the entire colonic mucosa needs to be visualised.  The 
lesions that require detection are too small to be reliably detected with other methods.  This is 
the reason why colonoscopy remains the gold standard for surveillance in our population 
group.  These patients are from a rural and isolated part of South Africa, with limited medical 
resources.  Colonoscopy offers each patient an opportunity at surveillance as well as 
diagnoses with one investigative tool.   
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1.3 Why is colonoscopy the best option? 
A colonoscopy is an endoscopic procedure using a flexible scope to assess the integrity, 
mucosal lining and general luminal surface anatomy of the colon.  A flexible scope is passed 
trans anally and navigated with care through the entire colon, from rectum up to caecum and 
ileo-caecal junction (figure 1).  During this procedure the wall and mucosa of the colon is 
assessed and inspected for pathology.  The colonic lumen is examined for any growth or 
abnormal lesion, bleeding foci or disruption in or narrowing of the lumen. The technique of a 
complete and thorough colonoscopy takes years of experience and bowel preparation plays a 
major role in achieving this goal and gaining the much needed experience.  Colonoscopic 
screening reduces death from colorectal carcinoma and can decrease the incidence of disease 
through removal of adenomatous polyps. 1   
Preparation and polyp miss rate plays a major role in the quality and accuracy of surveillance 
with colonoscopy.  
  Figure 1
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Even in this rural environment, colonoscopic surveillance is offered locally to this group of 
Lynch syndrome patients on an annual basis.  
Colonoscopy can cause considerable patient discomfort.  Poor preparation requires more air 
insufflation with added discomfort.  Discomfort will impact on patient compliance during the 
procedure with negative impact on surveillance.  What makes our study population unique is 
that most of the colonoscopies performed are performed on multiple members of high risk 
families.  One unpleasant, painful or distressing colonoscopy on one member of a family 
could trigger reluctance to further colonoscopic surveillance within the rest of that family.   
Good preparation is thus essential as only a minimal amount of sedation can be offered in the 
rural setting. 
1.4 Polyp miss rate 
In a systematic review, van Rijn et al reviewed polyp miss rate looking at both polyp size and 
polyp type.  A total of 465 patients were included.  All 465 patients underwent two, same day 
colonoscopies with polypectomy. 13   For any size polyp, the pooled miss rate was 22%.  
More specifically the adenoma miss rate was 2.1% for polyps larger than 10mm, 13% for 
adenomas 5 – 10mm and 26% for adenomas of 1 – 5mm. 13  It was concluded that polyps 
larger than 10 mm are rarely missed at colonoscopy, but the miss rate increases significantly 
as the polyp size decreases.  In their review of the literature, they found that one in five 
polyps is missed at colonoscopy. 13   Larger polyps are less likely to be missed, but some big 
adenomas might be overlooked.  One in four adenomas (1-5mm) may be missed.  
Unfortunately the number of studies looking at this specific topic is small. 13  
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Bressler et al reviewed the miss rate of right sided colon cancer in 4920 patients.  2654 
(53.9%) had had a colonoscopy within 3yrs prior to their diagnosis and of those patients,  
96%  had their most recent colonoscopy up to 6 months before admission, thus viewed as 
detected cancers. 14  105 patients or rather 4.0% had their most recent colonoscopy between 6 
and 36 months prior to admission, categorizing them as missed cancers.  The miss rate of 
right sided cancers in usual clinical practice was found to be 4.0%. 14 
Several studies established that in preventing colorectal cancer, colonoscopy is less effective 
in the proximal compared to the distal colon.  Reasons for this might be (1) poor colon 
preparation prior to colonoscopy affecting the visibility more on the right than on the left or 
(2) polyps in the proximal and distal colon tend to differ in both polyp size and type. 15-17  
Serrated, flat and depressed polyps being more prevalent proximally. 18-20 
 
1.5 What do we need to achieve quality colonoscopy? 
For a complete and thorough colonoscopy examination, the colon needs to be cleansed of any 
stool or obstructing debris.  If this is not done, it can result in: 
 
 Sub optimal visualization 
 Missed lesions 
 Technically difficult procedure 
 Patient discomfort and emotional trauma 
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 Poor surveillance compliance  
 Mucosal damage and potential perforation 
 
Even under optimal circumstances, polyp pick up rate is not 100%.  To give the endoscopist 
the best possible chance of identifying most of the polyps, the colon needs to be clean. 
Patients need to be compliant with preparation product instructions to ensure a clean colon 
prior to endoscopy.  This is not always possible as most bowel preparations are poorly 
tolerated contributing to poor compliance.   
 
1.6 What is unique about our population? 
Our cohort resides in a number of small, remote and rural towns in the Northern Cape 
Province.  Many only have basic medical services and support systems in place. This makes 
annual surveillance colonoscopies a logistic and financial challenge. As not all of the patients 
have adequate bathroom facilities and have to travel considerable distances to have their 
colonoscopies, some patients do not cope with the bowel cleansing regime during 
preparation.  The end result is a poorly prepared colon and an incomplete colonoscopy.  Their 
local medical facilities can unfortunately not offer them colonoscopies or alternative 
screening modalities.  With the outreach surveillance program, colonoscopy, as a screening 
and diagnostic tool, is now offered to these patients locally on an annual basis.                   
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This population group undergoes a single colonoscopy each year during the outreach 
program.  If for any reason the colonoscopy cannot be done, a year will pass before the next 
scope.  
What makes this study population so unique is the fact that none of them have used 
Moviprep® as colonic preparation previously.  Prior to 2013, preparation was either a 4 litre 
polyethylene glycol containing solution or a small volume phosphate soda preparation.  The 
latter solution now carries a FDA red label warning because of the possibility of development 
of nephrocalcinosis. 
The large volume of the traditional PEG was poorly tolerated.  This was the perfect 
opportunity to try and improve compliance and quality of bowel cleansing in the view of 
optimizing the surveillance program. 
 
1.7 Methods of colonic preparation prior to colonoscopy 
The 2013 European Society of Gastrointestinal Endoscopy (ESGE) guideline (Hassan et al), 
recommended a combination of low fibre diet prior to colonoscopy and a split regimen of 4 L 
of polyethylene glycol (PEG) solution (or a same-day regimen in the case of afternoon 
colonoscopy) for routine bowel preparation.  A split regimen (or same-day regimen in the 
case of afternoon colonoscopy) of 2 L PEG plus ascorbate or of sodium picosulphate plus 
magnesium citrate may be valid alternatives.  The ESGE advises against routine use of 
sodium phosphate. 21 
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In a randomised study, Katz et al compared sodium picosulfate and magnesium citrate 
(P/MC) with 2 L polyethylene glycol solution and two 5 mg bisacodyl tablets.              
Overall cleansing of the colon was equivalent, but patients reported that acceptability and 
tolerability was greater for P/MC. 22 
Komeda et al published an article in 2012 of factors associated with failed polyp retrieval at 
screening colonoscopy and found that small polyp size and rectal snare removal were found 
to be associated with polyp removal failure. Human factors such as fatigue or lapses in 
concentration conceivably could play a role in failure to retrieve polyps. However, there were 
no significant correlations found between retrieval rate and the number of polyps per patient, 
quality of bowel preparation, or length of procedure. 23 
Arora et al studied the efficiency of various bowel preparations in accomplishing colonic 
cleansing for optimal mucosal visualization during colonoscopy.  Powder PEG 350 alone and 
in combination with oral sodium phosphate was observed to be statistically superior to 
magnesium citrate. 24 
“Preparation for colonoscopy is essential before a colonoscopy” (Lozenzo-Zúniga et al 2012).  
This allows us to conduct a thorough examination of the entire colonic mucosa.  The ideal 
method of colon cleansing should be fast, safe with minimal discomfort to the patient.   
Although the efficiency of most preparations is comparable, it is patient preference and the 
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1.8 Preparation expectation and experience 
What do we, as clinicians, require from a preparation for colonic cleansing?  As mentioned 
before, colonic cleansing is essential and without thorough cleansing a thorough, safe and 
tolerable colonoscopy is not possible.  What patients expect from a colonic preparation and 
what they experience during the preparation period will impact on both the clinical findings 
and colonoscopic experience itself. 
In a systemic review conducted by McLachlan et al, the primary concern of patients 
(regardless of whether they had direct experience of a colonoscopy or whether they were 
considering it) was discomfort and inconvenience due to the use of laxative bowel 
preparation.  A significant majority judged this to be the worst part of the process, and the 
main barrier.  26 
Guidelines on the technical performance of colonoscopy have not recommended specific 
targets for rates of adequate preparation 27-28 because these rates are partly related to patient 
factors, such as poor socioeconomic status that typically vary between populations. 29-30 
Efficacy and tolerability are related, and together constitute the main ingredients of 
effectiveness.   If the preparation is not well tolerated, it will not be ingested and will be less 
effective, even if otherwise efficacious. 31 Thus, both efficacy and tolerability are important. 
Selection of a preparation would be easy if one preparation was clearly superior at both 
efficacy and tolerability, but such a preparation does not yet exist. 31 
Ideally the optimal bowel preparation should be uncomplicated to prepare, easy to consume 
and have a low side effect profile when considering fluid and electrolyte shifts, nausea and 
vomiting, abdominal discomfort, abdominal cramps.  Unfortunately a bowel cleansing regime 
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like this does not exist and one needs to tailor the specific needs, expectations, socio-
economic circumstances, disease profile and personality of each individual patient, to a 
specific bowel preparation regime.  
 
1.9 Evidence behind Moviprep®  
In a randomized trial comparing low volume PEG plus ascorbic acid to a standard 4L PEG 
plus electrolyte solution, by Christian Ell et al, it was found that there was no difference in 
gut cleansing or safety profile.  The only difference shown, was the combination of ascorbic 
acid and PEG solution (2L in total) reduced the volume patients had to consume for bowel 
cleansing compared to PEG and Electrolyte combinations (4L in total).  The low volume 
PEG + Ascorbic acid preparation was more acceptable to patients and should improve 
effectiveness in routine practice. 32 
Pelitari et al evaluated the effect of additional clear fluid intake to the standard Moviprep® 
regime.  Low volume 2L PEG and ascorbic acid (Moviprep®, Norgine Pharmaceuticals) has 
been demonstrated to be as effective as other bowel cleansing agents and has greater patient 
tolerability.  They evaluated whether the addition of clear fluids to the standard regime would 
improve bowel cleansing.  Patients were randomised to either receiving the standard 2L 
Moviprep® or standard 2L Moviprep® with an additional 1.5L clear fluid.  It was found that 
increasing the volume of clear fluid intake with Moviprep® improves cleansing in the distal 
colon and improves polyp detection rate. 33 
Kastenburg et al compared the colon cleansing efficacy of a 2L PEG + ascorbic acid to a 4L 
PEG solution.  The scoring system used in US NaP trials were used to grade overall colonic  
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cleansing (excellent: >90% mucosa seen, mostly liquid colonic contents, minimal suctioning 
for adequate visualization; good: >90% mucosa seen without significant suctioning needed; 
fair: >90% mucosa seen with a mixture of liquid/semisolid colonic contents, could be 
suctioned and/or washed; inadequate: >90% mucosa seen, contents could not be suctioned or 
washed).  High overall colon cleansing rates were observed for both 2L PEG and 4L PEG 
(88% and 96% respectively). 34  
Moviprep®, as a product, has been proven to be effective with equal cleansing outcomes 
when compared to other preparations.  In this study we planned to assess (1) the overall 
patient experience with Moviprep® and (2) the cleanliness of the colon after Moviprep® 
bowel preparation.  
A colonoscopy, in summary, needs to be done by a skilled and specialized clinician.  For 
maximal visualization of the mucosa during colonoscopy the colon needs to be clean and 
empty as the lesions in the above mentioned study group mostly populate the right side or 
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2.  AIM 
 
To evaluate the efficacy of Moviprep®, within the setting of a rural outreach program in the 
Northern Cape Province, in providing adequate right colon preparation for surveillance 
colonoscopy.   
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Background:  A cohort of subjects with Lynch Syndrome, undergo colonoscopic 
surveillance in the Northern Cape Province of South Africa over 1 week, annually.  Excellent 
preparation of the colon is essential to detect small right sided lesions.  This is difficult to 
achieve particularly in rural areas.  Distances to endoscopy facilities are also vast. 
 
Moviprep is a 2l polyethylene glycol (PEG) electrolyte solution containing ascorbic acid and 
sodium ascorbate marketed by Norgine Pharmaceuticals.  It is claimed that it provides a 
similar quality of preparation to the standard 4 l PEG preparation but with less volume and 
patient discomfort. 
 
Aim:  To evaluate Moviprep®, as a preparation for colonoscopy, in a cohort of subjects with 
Lynch syndrome in rural South Africa.   
 
Patients and Methods:  6 weeks prior to the colonoscopy surveillance week, a team 
travelled to the area to prepare the patients for colonoscopy.  After informed consent, 71 
individuals with an intact left colon and known to carry a C1528T mutation in the hMLH1 
gene, were individually counselled on the importance of bowel cleansing and the specific use 
of Moviprep®. During the surveillance week, 6 weeks later, colonoscopies were performed at 
4 venues in the Northern Cape.  Subjects completed a product acceptability questionnaire on 
arrival for surveillance colonoscopy.  The questionnaire evaluated the following aspects: ease 
of product preparation, prior experience with the product, acceptability and taste of the 
preparation, prior colonoscopy experience, volume of prep taken and occurrence of nausea 
and vomiting.   
 
The quality of preparation was assessed visually at colonoscopy by a single individual 
(DJdV).  The preparation was graded using the following criteria (The Harefield Cleansing 
Scale):  A = all colon segments clean; B = at least 1 segment with residual amounts of brown 
liquid or semisolid stool, which can easily be displaced or removed; C = at least 1 segment 
with only partially removable stool, preventing complete visualization; D = at least 1 segment 
which could not be examined due to solid stool).  Grades A or B were accepted as successful 
preparation and C or D would be considered failed preparation.   
This study was passed by the Research Ethics committee of the University of Cape Town 
(HREC REF:249/2013). 
 
Results:  64 of 71 (90%) subjects seen on the preparation trip completed the questionnaire.  
53 of 64 (83%) had used other colon preparations previously.  57 of 64 (89%) would prefer 
Moviprep® for their next colonoscopy. A total of 46 subjects of the 64 underwent 
colonoscopy.  41 of the 46 (89%) had acceptable colonic preparation as judged at endoscopy.   
Conclusion: Moviprep® provides adequate colonic cleansing in 89% of subjects undergoing 
surveillance colonoscopy in a rural setting.  A similar number would choose the same 
preparation for their next colonoscopy.  
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2.3 MAIN PAPER 
Introduction  
One of the factors that negatively affect polyp detection is an inadequately prepared colon.    
A cohort of individuals with Lynch Syndrome, (hMLH1 mutation C1528T), undergo a 
surveillance colonoscopy in small rural hospitals where endoscopy is not usually available as 
part of an outreach project.  There are major resource constraints within the region.  The 
nearest routine colonoscopy service is between 600 and 1200km away from where the at risk 
individuals live.    
The only bowel preparation available previously in the region was an oral phosphate soda 
type preparation.  There was some concern about this preparation because of the inability to 
ensure adequate fluid intake and pre-preparation fitness.  We therefore sourced a 4L PEG 
solution but compliance was an issue because of the large volume.  The availability of a 2L 
PEG ascorbic acid solution may address both the safety and compliance concerns.   
Aim 
The aim of this study was to assess the efficacy and acceptability of a 2L preparation of PEG 
with ascorbic acid and ascorbate.  The primary endpoint was the quality of colon preparation 
and the secondary endpoint was subject acceptability of the preparation. 
Methods 
The study was conducted in two main phases: 
Phase one.  
All known at risk individuals who require colonoscopic surveillance were identified.  A 1 
week preparation road trip was undertaken into the western part of South Africa from 7 July 
2013 until 12 July 2013.  The team consisted of  a professional nurse specialised in genetics, 
a genetics registrar, a professional endoscopy nurse, a representative of the Norgine 
pharmaceutical company and  a registrar in general surgery.  
14 towns were visited in the Northern Cape. Subjects received counselling on the importance 
of good bowel preparation for colonoscopy and each received an information sheet detailing 
the aim, methods and possible risks involved in this study in their home language. 
Where subjects could not be seen in person, a family member or the primary health care 
worker was requested to convey the information.  All subjects were given the choice between 
their usual bowel preparation, Klean-prep®, or using Moviprep® for the first time.  During 
this session, it was made clear to the patient that Moviprep® is not an experimental colonic 
preparation and that it has been well proven and studied in its efficacy and side effect profile.  
This study aimed to look at the efficacy and patient opinion of Moviprep® in a rural setting.  
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Moviprep® includes a detailed instructional pamphlet.  This pamphlet served as the 
standardised instruction during the counselling sessions.  This aided informing subjects on 
dietary requirements the day prior to colonoscopy, extra clear fluid intake and instructions on 
mixing the product.   
 
Each subject was given a choice on when to drink the two litres of Moviprep®. Either a 
single dose which consisted of  two litres of Moviprep® at 05h00 the morning of the 
colonoscopy or a split dose, consisting of  two litres of Moviprep® split up in one litre the 
night prior to- and the second litre the morning of the colonoscopy. 
Informed consent was obtained from all subjects participating in the study which included 
consent for the use of Moviprep® as bowel preparation as well as completion of a product 
acceptability questionnaire.   
Phase two. 
A weeklong trip was undertaken from 26 August 2013 till 30 August 2013 to the Northern 
Cape, with a 19 member team.  4 Pre-planned destinations included: Upington, Nababeep, 
Garies and Vredendal Hospitals. Fully equipped endoscopy units were set up in each centre.  
Questionnaires were completed by the patients awaiting their colonoscopies which assessed:  
 Compliance 
 Product satisfaction 
 Side effect profile 
 Comparison to other preparation products 
Prior to colonoscopy each subject’s colonic cleansing was assessed by a nurse who inspected 
the stool consistency.  Each subject noted to have particulate matter in his or her stool, was 
given an additional litre of bowel prep (Moviprep®).   
Every colonoscopy was evaluated and scored on cleanliness and quality of preparation by a 
single observer who was not doing the colonoscopy (DJdV).  The scoring was done during 
the course of each endoscopy using a validated colonic preparation scoring system, “The 
Harefield Cleansing Scale”. 
 
The Harefield Clensing Scale divides the colon into 6 segments (rectum, sigmoid, 
descending-, transverse- and ascending colon and cecum).  A grade ranging from A to D is 
awarded to each segment as follows:  
A = all colon segments clean; 
B = at least 1 segment with residual amounts of brown liquid or semisolid stool, which can 
easily be displaced or removed;  
C = at least 1 segment with only partially removable stool, preventing complete visualization; 
D = at least 1 segment which cannot be examined due to solid stool).  
Effectiveness of Moviprep® as colonic preparation – cleansing right colon for Lynch Syndrome (LS) screening 
A PROSPECTIVE STUDY  de Villiers DJ 
22 
 
Grade A or B was considered as a successful cleansing.  Grade C or D was considered a 
failed colonic preparation.  (Appendix C) 
 
All data processing was done with the aid of Microsoft Office Excel 2007.     
Results  
Phase one 
During the initial phase of the study a total of 71 boxes of Moviprep® were distributed to 
subjects.   48/71 (68%) were directly counselled and consented by DJdV and 16/71 (23%) 
received their counselling indirectly from a family member who attended the counselling 
session, or a professional nurse known to the patient. For a further 7 (10%) subjects, 
preparation was delivered to the local clinic but it was not possible to provide personalised 
instruction.  None of these 7 subjects arrived for their colonoscopies during the second phase 
of the study.   
Phase two 
64/71 (90%) subjects decided on Moviprep® as their colonic preparation and were willing to 
complete the questionnaire.  The remaining 7 did not attend on the day of their colonoscopy. 
These were the same individuals who could not be contacted during phase one of the 
outreach program.  
In total, 46/64 (72%) patients who had used Moviprep® and signed consent for the study had 
their colonoscopies done.  Due to logistic constraints at one of the venues, 18/64 (28%) 







                                          
Figure 1. Breakdown of scope numbers 
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9/46 (19%) patients received an extra litre of preparation. Of the 46 patients who had their 
colonoscopies performed, 41 subjects (89%) were graded A or B.  The remaining 5/46 (11%) 
C and D. (Figure 2) 
 






                   
  Figure 2.  Cleansing results       
      
Thus, of the 41 (89%) patients that had passed their colonic preparation, 26/41 (63%) 
received direct counselling from me and 15/41 (37%) indirect counselling from either a 
counselled family member or a professional nurse.  This was found to be statistically 
significant.  (p-value 0.02) 
Of the 5 (11%) patients who failed their colonic preparation, 4/5 (80%) were counselled 
















Figure 3.  Contact with patient during phase one. 
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When comparing single or split dose preparation of Moviprep®; 33 (80%) of the 41 patients 
who passed their colonic preparation had used the single dose method and 8/41 (20%) used 
the split dose method.  All the patients who had failed their colonic preparation (5/5) had 
used the single dose method. (Figure 4)  
 
 
Figure 4. Single versus split preparation 
 
A total of 18 subjects could not be colonoscoped due to logistic constraints at one of the 
venues.  Despite this they all completed a questionnaire.  At another venue, 7 patients did not 
arrive for their colonoscopies which brought the total of completed questionnaires to 64.    Of 
the 64 patients, 53(83%) had used a colonic cleansing preparation in the past.  None of these 
patients had ever used Moviprep® as colonic preparation prior to this study.  91% of the 53 
patients, who had used a different type of colonic preparation in the past, preferred using 
Moviprep® as their colonic preparation in the future.  When asked whether or not 
Moviprep® would be considered for future colonic preparation, 57/64 (89%) answered yes.  
18/64 (28%) reported an unpleasant taste and 46/64 (72%) reported the taste as being 
pleasant.  56/64 Patients found Moviprep®, as a product, easy to prepare and 63/64 patients 
reported that they had followed the instructions regarding diet and fluid intake during the 
preparation process. 
 
The side effect profile was found to be similar to most bowel preparation regimes. This 
included nausea and/or vomiting, abdominal cramps and a feeling of “hunger” during the 
preparation period.  Subjects were asked to rate each possible adverse reaction or event on a 
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scale of 1 to 5.  One being the least severe, and 5 most severe.  Of the 64 patients who had 
completed a questionnaire, 6% (4/64) experienced nausea rated at 5/5.  Abdominal cramps 
were experienced at a rating of 2/5 in 11% of subjects and 5/5 in 5% of subject.  The major 
adverse event experienced by subjects, were the sensation of “hunger” during the preparation 
phase.  Of the 64 subjects, 17% (11/64)  rated hunger at 5/5 and 23% (15/64) rated it at 2/5.  
 









 Figure 5. Breakdown of adverse events rated 5/5 in 40% (26/64) subjects 
 
Discussion  
Several studies established that in preventing colorectal cancer, colonoscopy is less effective 
in the proximal compared to the distal colon.  Reasons for this might be poor colon 
preparation prior to colonoscopy or the fact that polyps in the proximal colon tend to be more 
difficult to detect. 1-3 Without proper colonic cleansing a complete and thorough investigation 
is impossible, not to mention the higher risk of patient discomfort and possible complications 
related to the procedure itself.   
In this study population, colonoscopy was performed in patients with a high risk of 
developing colon cancer and the lesions are mostly encountered on the right side of the colon.  
This emphasises a clean colon even more.  These patients live in a rural part of South Africa 
and are screened annually by colonoscopy.  It is thus very important, in this rural setting, that 
every colonoscopy is preceded by optimal bowel cleansing. 
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During this study we offered a cohort of patients an alternative colonic preparation to what 
they are used to.  This product is marketed as being half the usual volume, 2 litres compared 
to 4 litres, as well as having a more pleasant taste.  This should make the likelihood of the 
patient completing his/her preparation regime much higher.  
In a systematic review by van Rijn et al 2006, they reviewed polyp miss rate looking at both 
polyp size and polyp type.  A total of 465 colonoscopies were reviewed. 6   Adenoma miss 
rate was 2.1% for polyps larger than 10mm, 13% for adenomas 5 – 10mm and 26% for 
adenomas of 1 – 5mm.  Polyps larger than 10 mm are rarely missed at colonoscopy, but the 
miss rate increases significantly as the polyp size decreases. 6   In their review of the 
literature, they found that one in five polyps is missed at colonoscopy.  Larger polyps are less 
likely to be missed, but some big adenomas might be overlooked.  One in four adenomas (1-
5mm) may be missed.  Unfortunately the number of studies looking at this specific topic is 
small. 6   
Bressler et al reviewed the miss rate of right sided colon cancer in 4920 patients.  All of these 
patients had established and confirmed right sided colon cancer. 7   2654 (53.9%) had had a 
colonoscopy within 3yrs of their diagnoses being made.  Of the 2654 patients, 96% had their 
most recent colonoscopy up to 6 months before admission, thus viewed as detected cancers. 7  
105 patients or rather 4.0% had their most recent colonoscopy between 6 and 36 months prior 
to admission, categorizing them as missed cancers The miss rate of right sided cancers in 
usual clinical practice was found to be 4.0%. 7   
Of the 71 patients approached for this study regarding the use of Moviprep®, 64 were 
enrolled in the study and 46 colonoscopies were evaluated for colonic cleansing.  Data clearly 
shows that Moviprep® can be used, for colonic preparation in the rural setting, with great 
success. This was proven with successful cleansing in 89% of all scoped patients.  A similar 
percentage of patients were satisfied with Moviprep® and would prefer using it in the future 
for colonic preparation.   
 
Colonic preparation will never be viewed as a convenient and easy process.  What we 
essentially induce in our patients is diarrhoea with nausea and vomiting in some cases.  With 
this being said, one can understand that some patients find it very difficult to complete a 
course of colonic preparation despite the risk of an incomplete colonoscopy.  The main drive 
behind this study was to see if we can offer patients, in this study group, an alternative to 
what they are used to.  While doing this, we have proven the product as being effective, even 
in a rural community with minimal resources. 
Conclusion    
Moviprep® can effectively be used in the rural setting for bowel cleansing with proven 
patient satisfaction.  The feedback and data derived from this study proved the above and the 
author hopes that he can offer the same product, even as an alternative, to the cohort of 
patients along the west coast of South Africa in the future. 
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A lot of emphasis is placed on bowel preparation prior to colonoscopy with good reason, as 
stipulated before.  The patients in this cohort cannot afford missing out on a single 
surveillance colonoscopy, especially not due to poor bowel cleansing.  Here we have proven 
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Introduction 
You are invited to participate in a study evaluating the effectiveness of Moviprep® in 
cleaning the colon in preparation for colonoscopy.  Moviprep® is a bowel preparation 
specifically designed for bowel cleansing.   
A study group of about 100 patients who undergo yearly colonoscopy will be asked to enrol 
in the study.     
Nature of research and purpose of the study 
Moviprep® is a product manufactured by the Norgine group of Companies.  It is a well 
established product specifically directed at bowel cleansing.  Norgine donated Moviprep® to 
the 2013 Colonoscopy outreach programme and we decided to test its efficacy during a trial  
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which will run during the outreach programme.   Preparation of the colon prior to 
colonoscopy is an essential part of the preparation process. 
 If the colon is not cleaned properly it is impossible to do a complete and thorough 
colonoscopy.  This product, Moviprep®, is a bowel preparation said to be effective in 
cleaning the colon and easy to use.  With this study we will evaluate whether or not 
Moviprep® cleans the bowel well enough to do a complete colonoscopy.   
In general, patients in rural parts of the country use whatever product is available from their 
local hospital and clinic.   These products, e.g. fleet enemas, laxatives etc. are not always 
specifically indicated for bowel preparation and are either uncomfortable or difficult to use or 
may result in poor bowel preparation.  Poor bowel preparation may mean that the doctor 
cannot see all the areas of the colon necessary for proper screening.  
What do I have to do if I agree to take part in the study? 
The product, Moviprep®, will be supplied to you with specific instructions on its use.    
The product, 2 L in total, must be taken one day before the procedure in two divided doses. 
Agree to answer a few questions before or after the colonoscopy regarding your experience 
with Moviprep® e.g. taste, ease of preparation, ill effects etc.  
Possible risks and benefits 
This product is not an experimental medication and is freely available on the market since 
2006 and is safe.  It is a well known bowel preparation in the private sector. As with any 
pharmaceutical product on the market, and with most colonic preparations, one should expect 
possible risks of experiencing ill effects or adverse reactions.   
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Risks or adverse effects: 
Any patient, who has used the product before and experienced adverse effects or severe 
allergic reactions, should not use this product again.  Diarrhoea is an expected outcome of 
bowel preparation but other gastro-intestinal side effects can often occur.  This would include 
nausea, vomiting, bloating, abdominal pain, anal irritation and sleep disturbance and may 
vary between different preparations.  These might only occur when the product is used and 
will resolve spontaneously shortly after colonoscopy. 
The risk of poor bowel preparation is very low as the product is designed to induce diarrhoea 
and bowel cleansing.  We will specifically look at the quality of bowel cleansing that this 
product produces on the day of colonoscopy. 
Benefits  
The product is marketed as having a pleasant taste compared to other products on the market.  
The entire preparation consists of two oral doses of 1L each compared to other preparations 
consisting of 4L in total.  Preparation is easy and no rectal administration required.  There is 
also a chance that the doctor’s ability to view to colon may be better with this product than 
with less suitable bowel preparations, e.g. fleet enemas that may be available from your local 
clinic or hospital.  
Other options 
It is your own free choice to take part in this study.  If at any stage you decide against the use 
of Moviprep®, or not to participate in the study, we will provide you with another good 
quality bowel cleansing product.   
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If you agreed to take part you will not be identified by name in any of the data or any 
publication of the results.  The results of your colonoscopy and any other private medical 
information will be protected and kept confidential.  
Contact details 
If you have any questions regarding the product or the study please contact the 
following people: 
Dr. D.J. de Villiers – 083 422 3162 
Sr. Ursula Algar – (021) 404 5499 
If you are concerned that your rights as a research participant has not been respected 
please contact the following committee:  
Faculty of Health Sciences – Human Research Ethics Committee   
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Consent Form to participate in medical research 
Title:  Effectiveness of Moviprep® as colonic preparation – cleansing right 
colon for Lynch Syndrome (LS) screening 
Authors:  Dr. DJ de Villiers, Prof. PA Goldberg, Sr. U Algar 
Contact for research:  Dr. DJ de Villiers (Tel:  083 422 3162 e-mail:  devilldj@gmail.com) 
I, ___________________________ hereby agree to participate in the research project 
evaluating the effectiveness of Moviprep® in cleansing the right/ascending colon prior to 
colonoscopy being done.  The risks and benefits have been explained to me by Dr. DJ de 
Villiers and Sr. Ursula Algar which I understand and have been given the opportunity to ask 
questions.  
I understand that my participation in this study is entirely voluntary and as colonic preparation is an 
absolute necessity prior to colonoscopy I can contact Dr. DJ de Villiers or Sr. Ursula Algar if I prefer 
using an alternative preparation to Moviprep® and not continue with the study. 
I understand there will not be any financial compensation involved for participation in this 
research.   
If you agreed to take part you will not be identified by name in any of the data or any 
publication of the results.  The results of your colonoscopy and any other private medical 
information will be protected and kept confidential.  
 
________________________      _____________________ 




_______________________      _____________________ 
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Please tick appropriate box 
1. Was Moviprep® easy to prepare? 
□Yes   □No 
2. Did you follow the instructions on preparing Moviprep®? 
□Yes   □No 
3. Did you follow the instructions on diet and fluid intake during preparation? 
□Yes   □No 
4. Did you take 2L of Moviprep® in total? 
□Yes   □No 
5. Was a litre a day for two days to much to drink?  
□Yes   □No 
6. Did Moviprep®, in your opinion, have a bad or pleasant taste? 
□Bad   □Pleasant 
7.  Was Moviprep® easy or difficult to swallow? 
□Difficult   □Easy 
8. Have you used other preparations before? 
□Yes   □No 
9. If yes in question 8, was Moviprep® easier to take than other preparations? 
Use a 1 to 5 scale with 1 difficult and 5 very easy 
□1  □2       □3  □4        □5 
10. Did you experience any side effects after taking Moviprep®? 
□Yes   □No 
 
11. Please indicate whether you experienced any of the following: 
Use a scale from 1 to 5 with 1 being none and 5 severe 
Nausea   □1  □2       □3  □4        □5  
  
Rash   □1  □2       □3  □4        □5 
  
Vomiting    □1  □2       □3  □4        □5 
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Itchiness   □1  □2       □3  □4        □5 
  
Abdominal cramps □1  □2       □3  □4        □5 
     
Limb swelling  □1  □2       □3  □4        □5 
  
Abdominal pain  □1  □2       □3  □4        □5 
     
Hunger   □1  □2       □3  □4        □5 
  
Abdominal distension □1  □2       □3  □4        □5 
     
Dizziness   □1  □2       □3  □4        □5 
  
Anal irritation  □1  □2       □3  □4        □5 
     
Headache   □1  □2       □3  □4        □5 
  
Sleep disturbance  □1  □2       □3  □4        □5 
     
Shortness of breath □1  □2       □3  □4        □5 
 
12. Would you consider using Moviprep® in future as bowel preparation for colonoscopy? 
□Yes   □No 
13. Would you recommend Moviprep® to a friend or family member as bowel preparation 
prior to colonoscopy? 
□Yes   □No 
14. In your opinion, was Moviprep® effective in cleaning your bowel? 
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Effectiveness of Moviprep® as colonic preparation – cleansing right colon for Lynch Syndrome (LS) screening 






Effectiveness of Moviprep® as colonic preparation – cleansing right colon for Lynch Syndrome (LS) screening 
A PROSPECTIVE STUDY de Villiers DJ
41 
Appendix F 
Effectiveness of Moviprep® as colonic preparation – cleansing right colon for Lynch Syndrome (LS) screening 
A PROSPECTIVE STUDY de Villiers DJ
42 
Appendix G 
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